BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30070597)

  • 1. Predicting the profile of increasing disability in multiple sclerosis.
    Tomassini V; Fanelli F; Prosperini L; Cerqua R; Cavalla P; Pozzilli C
    Mult Scler; 2019 Aug; 25(9):1306-1315. PubMed ID: 30070597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How patients with multiple sclerosis acquire disability.
    Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
    Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
    Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
    Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Goodin DS; Reder AT; Traboulsee AL; Li DK; Langdon D; Cutter G; Cook S; O'Donnell T; Kremenchutzky M; Oger J; Koelbach R; Pohl C; Wicklein EM;
    Mult Scler; 2019 May; 25(6):837-847. PubMed ID: 29761737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
    Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapses add to permanent disability in relapsing multiple sclerosis patients.
    Koch-Henriksen N; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
    Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
    Hechenberger S; Helmlinger B; Ropele S; Pirpamer L; Bachmaier G; Damulina A; Pichler A; Khalil M; Enzinger C; Pinter D
    Mult Scler Relat Disord; 2022 Jan; 57():103353. PubMed ID: 35158430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
    Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
    Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
    Usta NC; Boz C; Terzi M
    Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Prosperini L; Borriello G; De Giglio L; Leonardi L; Barletta V; Pozzilli C
    BMC Neurol; 2011 Feb; 11():26. PubMed ID: 21352517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
    Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
    Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
    Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
    Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.